Small Cell Lung Cancer Transformation as a Mechanism of Resistance to PD-1 Therapy in KRAS-Mutant Lung Adenocarcinoma: A Report of Two Cases
Wade T. Iams(Vanderbilt University Medical Center), Christine M. Lovly(Dana-Farber Cancer Institute), Karinna Almodovar(Vanderbilt University Medical Center), Leora Horn(Vanderbilt University), Lee P. Lim, Kathryn E. Beckermann(Vanderbilt University Medical Center), Christopher K. Raymond(Bellevue Hospital Center), Jennifer Hernandez, Cindy L. Vnencak‐Jones(Vanderbilt University)
Cited by 43
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Mechanisms of receptor tyrosine kinase activation in cancer
|Molecular Cancer|2018|1.1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k